US EditionPublished • loading... • Updated
Europe Approves Bayer Drug for Menopause Hot Flashes
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The European Commission has granted marketing authorisation in the European Union for elinzanetant under the brand name Lynkuet. This compound is approved for the treatment of vasomotor symptoms (SVM; commonly known as hot flashes) from moderate to severe associated menopause or caused by endocrine adjuvant therapy (AET) in breast cancer. “The European approval of Lynkuet provides a new therapeutic option for women whose vasomotor symptoms signi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
